Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Marina Biotech ($MRNA) stock shot up in its previous trading session as the company announced that the European Patent Office holds positive opinion for its Bacteria Mediated Gene Silencing. The claim is concerned with the company’s tkRNAi technology being utilized in its CEQ508 program that is being developed to treat familial adenomatous polyposis (FAP). The company’s current related portfolio consists of14 issued global patents.
Marina Biotech reported that the company is excited about the development. The stock touched the intraday high of $0.17 and finally closed at $0.169, up 12.67%. The jump helped in curtailing the losing streak for the stock which has lost over 36% of its value in the past one year.

Johnson & Johnson ($JNJ) received a reprieve as US District Judge Ed Kinkeade significantly reduced the compensation payable by the company to plaintiffs who were injured by its DePuy unit's hip implants. Initially, the Pharmaceuticals company was ordered to pay $1 billion in compensation. However, the latest development will shave off nearly $500 million off this amount.
The judge cited “constitutional considerations” for imposing the limits. However, he upheld that the implants were poorly designed. The fact that the companies did not disclose the risk properly to the consumers also was upheld. The company stock has gained 12% in the past one year.


• Sanofi ($SNY) announced that the exchange of its animal health business with Boehringer Ingelheim's consumer healthcare unit has been successfully closed in most markets effective January 1.
• IDEXX Laboratories ($IDXX) is set to join the S&P 500, effective after the close on Jan. 4. It will replace St. Jude Medical (NYSE:STJ), which has been acquired by Abbott Laboratories.

• ContraVir Pharmaceuticals ($CTRV) received a $297,875 CAD research grant to support the advancement of CRV431, the company's cyclophilin inhibitor in preclinical development for the treatment of hepatitis B virus (HBV) infection. The grant has been given by Canada's National Research Council.
• Lannett Company's ($LCI) receives the FDA approval for its Abbreviated New Drug Application (ANDA) for Lopinavir and Ritonavir Oral Solution USP, 80 mg/20 mg/mL for the treatment of HIV-1 infection, the therapeutic equivalent to AbbVie's (ABBV -0.7%) Kaletra Oral Solution.

• Community Health Systems ($CYH) announced that a subsidiary of the Company has completed the sale of a majority ownership interest in the Company’s Home Health division to a subsidiary of Almost Family ($AFAM). The transaction is worth nearly $128M, subject to adjustments.
• Soligenix ($SNGX) announced extending its agreement with Emergent BioSolutions (EBS) to develop RiVax, a vaccine for ricin exposure.

• CytomX Therapeutics Inc. ($CTMX) received a Hold rating from Oppenheimer.
• Gilead Sciences ($GILD) receives buy rating from RBC Capital. Its price target has been set at $90 apiece.

Gainers (% price change) Last Trade Change Mkt Cap
Pacific Biosciences of
4.36 +0.56 (14.74%) 401.82M
Depomed Inc
20.34 +2.32 (12.87%) 1.28B
Pacira Pharmaceuticals
34.75 +2.45 (7.59%) 1.34B
Insys Therapeutics Inc
9.86 +0.66 (7.17%) 705.35M
Allscripts Healthcare
10.93 +0.72 (7.05%) 1.98B
Losers (% price change)
Simulations Plus, Inc.
9.00 -0.65 (-6.74%) 160.05M
Oclaro, Inc.
8.41 -0.54 (-6.03%) 1.37B
Harvard Bioscience, Inc.
2.90 -0.15 (-4.92%) 104.84M
China Cord Blood Corp
5.82 -0.30 (-4.90%) 475.37M
Endologix, Inc.
5.51 -0.21 (-3.67%) 440.24M
Most Actives (dollar volume)
Gilead Sciences, Inc.
74.16 +2.55 (3.56%) 97.00B
Medtronic PLC
70.61 -0.64 (-0.90%) 97.95B
Pfizer Inc.
33.00 +0.52 (1.60%) 200.19B
Merck & Co., Inc.
60.15 +1.28 (2.17%) 165.36B
Johnson & Johnson
115.84 +0.64 (0.56%) 314.38B